| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 85 | 2025 | 621 | 14.150 |
Why?
|
| Mice, Inbred NOD | 94 | 2025 | 525 | 6.130 |
Why?
|
| Diabetes Mellitus, Experimental | 9 | 2024 | 199 | 3.660 |
Why?
|
| CD8-Positive T-Lymphocytes | 35 | 2023 | 677 | 3.580 |
Why?
|
| Mice | 101 | 2025 | 10844 | 2.390 |
Why?
|
| T-Lymphocytes, Regulatory | 16 | 2025 | 212 | 2.020 |
Why?
|
| Mice, Transgenic | 35 | 2023 | 1277 | 2.010 |
Why?
|
| Disease Models, Animal | 22 | 2024 | 2187 | 1.760 |
Why?
|
| Islets of Langerhans | 26 | 2023 | 279 | 1.720 |
Why?
|
| HLA-DQ Antigens | 2 | 2024 | 14 | 1.720 |
Why?
|
| Animals | 106 | 2025 | 20660 | 1.690 |
Why?
|
| Lymphocyte Activation | 17 | 2020 | 758 | 1.620 |
Why?
|
| Immune Tolerance | 11 | 2022 | 176 | 1.510 |
Why?
|
| CD4-Positive T-Lymphocytes | 13 | 2023 | 641 | 1.410 |
Why?
|
| Genetic Predisposition to Disease | 18 | 2019 | 719 | 1.390 |
Why?
|
| Autoimmunity | 16 | 2024 | 238 | 1.360 |
Why?
|
| Autoantigens | 13 | 2018 | 137 | 1.270 |
Why?
|
| Insulin-Secreting Cells | 9 | 2020 | 189 | 1.260 |
Why?
|
| HLA-A2 Antigen | 6 | 2018 | 64 | 1.250 |
Why?
|
| Autoimmune Diseases | 5 | 2022 | 230 | 1.230 |
Why?
|
| Major Histocompatibility Complex | 6 | 2009 | 88 | 1.150 |
Why?
|
| B-Lymphocytes, Regulatory | 2 | 2017 | 5 | 1.100 |
Why?
|
| Thymus Gland | 5 | 2018 | 233 | 1.060 |
Why?
|
| HLA Antigens | 3 | 2016 | 63 | 1.060 |
Why?
|
| Pancreas | 5 | 2020 | 151 | 1.040 |
Why?
|
| B-Lymphocytes | 9 | 2025 | 572 | 1.030 |
Why?
|
| Antigen-Presenting Cells | 8 | 2010 | 178 | 0.990 |
Why?
|
| B-Lymphocyte Subsets | 7 | 2019 | 46 | 0.980 |
Why?
|
| Interferon-gamma | 6 | 2021 | 567 | 0.880 |
Why?
|
| Myositis | 1 | 2024 | 5 | 0.870 |
Why?
|
| Mice, Knockout | 20 | 2025 | 2109 | 0.850 |
Why?
|
| T-Lymphocyte Subsets | 6 | 2019 | 247 | 0.830 |
Why?
|
| Mice, Inbred C57BL | 26 | 2025 | 3396 | 0.810 |
Why?
|
| Myocarditis | 1 | 2024 | 67 | 0.800 |
Why?
|
| Killer Cells, Natural | 5 | 2009 | 217 | 0.770 |
Why?
|
| Adoptive Transfer | 8 | 2016 | 148 | 0.760 |
Why?
|
| Mice, SCID | 13 | 2020 | 519 | 0.740 |
Why?
|
| Dendritic Cells | 8 | 2013 | 525 | 0.740 |
Why?
|
| Spleen | 11 | 2025 | 483 | 0.730 |
Why?
|
| T-Lymphocytes | 6 | 2021 | 1007 | 0.720 |
Why?
|
| HLA-B Antigens | 2 | 2018 | 13 | 0.710 |
Why?
|
| Natural Killer T-Cells | 4 | 2020 | 29 | 0.690 |
Why?
|
| Neuritis, Autoimmune, Experimental | 1 | 2020 | 1 | 0.680 |
Why?
|
| Nerve Tissue | 1 | 2020 | 6 | 0.680 |
Why?
|
| Histocompatibility Antigens Class I | 6 | 2018 | 144 | 0.680 |
Why?
|
| Cells, Cultured | 14 | 2020 | 2157 | 0.670 |
Why?
|
| Receptors, Antigen, T-Cell | 9 | 2023 | 287 | 0.650 |
Why?
|
| Rituximab | 2 | 2017 | 87 | 0.620 |
Why?
|
| Immunotherapy | 4 | 2025 | 255 | 0.600 |
Why?
|
| Insulin | 11 | 2023 | 686 | 0.600 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2018 | 12 | 0.590 |
Why?
|
| I-kappa B Proteins | 1 | 2018 | 39 | 0.580 |
Why?
|
| beta 2-Microglobulin | 2 | 2018 | 49 | 0.580 |
Why?
|
| B-Cell Activating Factor | 1 | 2017 | 9 | 0.560 |
Why?
|
| Female | 52 | 2025 | 32878 | 0.560 |
Why?
|
| Clonal Deletion | 4 | 2018 | 11 | 0.550 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2017 | 41 | 0.540 |
Why?
|
| Antigen Presentation | 7 | 2019 | 237 | 0.540 |
Why?
|
| Peptides | 6 | 2019 | 574 | 0.530 |
Why?
|
| H-2 Antigens | 6 | 2007 | 67 | 0.530 |
Why?
|
| Autoantibodies | 8 | 2017 | 182 | 0.510 |
Why?
|
| Cytidine Deaminase | 1 | 2017 | 86 | 0.500 |
Why?
|
| ADP-ribosyl Cyclase 1 | 4 | 2011 | 28 | 0.480 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2015 | 71 | 0.480 |
Why?
|
| Lymph Nodes | 3 | 2025 | 226 | 0.480 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2015 | 57 | 0.470 |
Why?
|
| Lymphocyte Depletion | 6 | 2017 | 99 | 0.470 |
Why?
|
| Humans | 39 | 2025 | 63446 | 0.460 |
Why?
|
| ADP Ribose Transferases | 3 | 2009 | 62 | 0.440 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2019 | 489 | 0.420 |
Why?
|
| Neoplasms | 1 | 2024 | 1364 | 0.410 |
Why?
|
| Cell Differentiation | 10 | 2020 | 1353 | 0.410 |
Why?
|
| Transplantation Tolerance | 4 | 2006 | 65 | 0.400 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2009 | 46 | 0.390 |
Why?
|
| Carrier Proteins | 1 | 2017 | 707 | 0.390 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 778 | 0.380 |
Why?
|
| Antigens, CD20 | 1 | 2011 | 14 | 0.370 |
Why?
|
| Receptors, Calcitriol | 1 | 2011 | 34 | 0.360 |
Why?
|
| Hypocalcemia | 1 | 2011 | 19 | 0.360 |
Why?
|
| Sjogren's Syndrome | 3 | 2020 | 24 | 0.360 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2008 | 119 | 0.350 |
Why?
|
| Receptors, Purinergic P2X7 | 1 | 2011 | 9 | 0.350 |
Why?
|
| Radiation Chimera | 4 | 2012 | 58 | 0.350 |
Why?
|
| Immunity, Mucosal | 2 | 2021 | 52 | 0.350 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1537 | 0.340 |
Why?
|
| Glucose-6-Phosphatase | 6 | 2020 | 15 | 0.340 |
Why?
|
| Transgenes | 4 | 2010 | 187 | 0.330 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2025 | 59 | 0.330 |
Why?
|
| HLA-A Antigens | 2 | 2007 | 9 | 0.320 |
Why?
|
| Mice, Congenic | 8 | 2016 | 22 | 0.310 |
Why?
|
| Chromosome Mapping | 5 | 2019 | 289 | 0.310 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 220 | 0.310 |
Why?
|
| Cell Movement | 4 | 2005 | 453 | 0.300 |
Why?
|
| Genetic Markers | 5 | 2012 | 130 | 0.290 |
Why?
|
| Calcium | 1 | 2011 | 575 | 0.280 |
Why?
|
| Alleles | 6 | 2019 | 448 | 0.280 |
Why?
|
| Antigens, CD1 | 1 | 2007 | 41 | 0.270 |
Why?
|
| Genetic Loci | 2 | 2019 | 116 | 0.270 |
Why?
|
| Gene Deletion | 2 | 2006 | 309 | 0.270 |
Why?
|
| Membrane Glycoproteins | 4 | 2020 | 669 | 0.260 |
Why?
|
| Th1 Cells | 3 | 2019 | 173 | 0.260 |
Why?
|
| CD27 Ligand | 2 | 2020 | 3 | 0.250 |
Why?
|
| Male | 27 | 2021 | 29889 | 0.250 |
Why?
|
| Interleukin-4 | 2 | 2013 | 141 | 0.250 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2019 | 182 | 0.250 |
Why?
|
| Clone Cells | 7 | 2008 | 114 | 0.230 |
Why?
|
| Adenovirus E3 Proteins | 1 | 2005 | 2 | 0.230 |
Why?
|
| Enterovirus B, Human | 1 | 2005 | 17 | 0.230 |
Why?
|
| Enterovirus Infections | 1 | 2005 | 12 | 0.230 |
Why?
|
| Peptide Fragments | 4 | 2013 | 410 | 0.230 |
Why?
|
| Islets of Langerhans Transplantation | 4 | 2008 | 176 | 0.230 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 2020 | 109 | 0.220 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2008 | 352 | 0.220 |
Why?
|
| Cytokines | 4 | 2019 | 935 | 0.220 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 158 | 0.210 |
Why?
|
| Clonal Anergy | 4 | 2019 | 23 | 0.210 |
Why?
|
| Graft Survival | 6 | 2008 | 289 | 0.210 |
Why?
|
| Mice, Inbred BALB C | 5 | 2021 | 883 | 0.210 |
Why?
|
| CRISPR-Cas Systems | 2 | 2018 | 361 | 0.210 |
Why?
|
| Inflammation | 5 | 2020 | 1147 | 0.210 |
Why?
|
| Disease Susceptibility | 2 | 2018 | 165 | 0.200 |
Why?
|
| Nervous System Autoimmune Disease, Experimental | 1 | 2003 | 2 | 0.200 |
Why?
|
| Paralysis | 1 | 2003 | 17 | 0.200 |
Why?
|
| Receptors, Interferon | 1 | 2003 | 21 | 0.200 |
Why?
|
| Interleukins | 2 | 2021 | 80 | 0.200 |
Why?
|
| Cell Death | 1 | 2004 | 284 | 0.200 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2004 | 182 | 0.200 |
Why?
|
| Proteins | 5 | 2011 | 750 | 0.200 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2 | 2020 | 3 | 0.200 |
Why?
|
| Adenoviridae | 1 | 2003 | 127 | 0.200 |
Why?
|
| Genome, Viral | 1 | 2003 | 136 | 0.190 |
Why?
|
| STAT1 Transcription Factor | 3 | 2021 | 34 | 0.190 |
Why?
|
| Receptors, Immunologic | 1 | 2002 | 177 | 0.190 |
Why?
|
| CD4 Antigens | 3 | 2020 | 149 | 0.180 |
Why?
|
| Mycoses | 1 | 2021 | 46 | 0.180 |
Why?
|
| Candidiasis, Chronic Mucocutaneous | 1 | 2021 | 1 | 0.180 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2021 | 4 | 0.180 |
Why?
|
| Lacrimal Apparatus | 1 | 2020 | 5 | 0.170 |
Why?
|
| Microbiota | 1 | 2023 | 129 | 0.170 |
Why?
|
| Cell Proliferation | 4 | 2017 | 988 | 0.170 |
Why?
|
| Thymocytes | 1 | 2020 | 21 | 0.170 |
Why?
|
| 4-1BB Ligand | 1 | 2020 | 1 | 0.170 |
Why?
|
| Candida albicans | 1 | 2021 | 72 | 0.170 |
Why?
|
| Pancreas, Exocrine | 1 | 2020 | 12 | 0.170 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2020 | 103 | 0.160 |
Why?
|
| Serum Albumin, Human | 1 | 2019 | 7 | 0.160 |
Why?
|
| Amino Acid Sequence | 5 | 2014 | 1592 | 0.160 |
Why?
|
| Protein Precursors | 1 | 2019 | 83 | 0.160 |
Why?
|
| Genetic Variation | 3 | 2015 | 383 | 0.150 |
Why?
|
| CD11c Antigen | 1 | 2019 | 8 | 0.150 |
Why?
|
| Receptors, Cell Surface | 3 | 2013 | 429 | 0.150 |
Why?
|
| Gene Targeting | 1 | 2019 | 77 | 0.150 |
Why?
|
| Adjuvants, Immunologic | 2 | 2013 | 227 | 0.150 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 373 | 0.140 |
Why?
|
| CD40 Antigens | 2 | 2016 | 60 | 0.140 |
Why?
|
| CD8 Antigens | 2 | 2008 | 54 | 0.140 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2017 | 5 | 0.140 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 191 | 0.140 |
Why?
|
| Galactosylceramides | 2 | 2009 | 11 | 0.140 |
Why?
|
| Bone Marrow Cells | 4 | 2016 | 238 | 0.140 |
Why?
|
| Macrophages | 5 | 2007 | 1039 | 0.140 |
Why?
|
| Ampicillin | 1 | 2017 | 12 | 0.140 |
Why?
|
| 5'-Nucleotidase | 1 | 2017 | 2 | 0.140 |
Why?
|
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 2017 | 6 | 0.140 |
Why?
|
| Gram-Positive Bacteria | 1 | 2017 | 36 | 0.130 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2017 | 15 | 0.130 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2017 | 30 | 0.130 |
Why?
|
| Prediabetic State | 2 | 2011 | 53 | 0.130 |
Why?
|
| Specific Pathogen-Free Organisms | 3 | 2019 | 42 | 0.130 |
Why?
|
| STAT4 Transcription Factor | 1 | 2016 | 8 | 0.130 |
Why?
|
| Signal Transduction | 5 | 2020 | 3035 | 0.130 |
Why?
|
| Interleukin-10 | 1 | 2017 | 160 | 0.130 |
Why?
|
| Peripherins | 2 | 2014 | 14 | 0.130 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2017 | 83 | 0.130 |
Why?
|
| Quantitative Trait Loci | 2 | 2025 | 75 | 0.130 |
Why?
|
| Intestines | 1 | 2017 | 165 | 0.120 |
Why?
|
| Skin Transplantation | 3 | 2006 | 154 | 0.120 |
Why?
|
| Antigens, CD | 3 | 2013 | 347 | 0.120 |
Why?
|
| DNA-Binding Proteins | 3 | 2020 | 1186 | 0.120 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2015 | 6 | 0.120 |
Why?
|
| Immune System | 1 | 2016 | 130 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 542 | 0.120 |
Why?
|
| Cytotoxicity, Immunologic | 5 | 2008 | 148 | 0.120 |
Why?
|
| Lectins, C-Type | 2 | 2013 | 89 | 0.120 |
Why?
|
| Crosses, Genetic | 3 | 2012 | 110 | 0.120 |
Why?
|
| Haplotypes | 2 | 2007 | 131 | 0.120 |
Why?
|
| Retinal Degeneration | 1 | 2015 | 27 | 0.120 |
Why?
|
| Antibodies | 3 | 2013 | 183 | 0.110 |
Why?
|
| Flow Cytometry | 4 | 2009 | 664 | 0.110 |
Why?
|
| Transplantation, Heterologous | 2 | 2005 | 229 | 0.110 |
Why?
|
| Dog Diseases | 1 | 2015 | 60 | 0.110 |
Why?
|
| Chromosomes, Mammalian | 2 | 2012 | 34 | 0.110 |
Why?
|
| Solubility | 2 | 2005 | 180 | 0.110 |
Why?
|
| Cholera Toxin | 1 | 2013 | 7 | 0.110 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 435 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 236 | 0.100 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 373 | 0.100 |
Why?
|
| Immunity, Innate | 4 | 2007 | 795 | 0.100 |
Why?
|
| B7-H1 Antigen | 1 | 2013 | 57 | 0.100 |
Why?
|
| Crystallography, X-Ray | 1 | 2014 | 433 | 0.100 |
Why?
|
| Antigens | 1 | 2013 | 147 | 0.100 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2012 | 2 | 0.100 |
Why?
|
| Gene Expression Regulation | 4 | 2020 | 1617 | 0.100 |
Why?
|
| Disease Progression | 3 | 2014 | 1172 | 0.100 |
Why?
|
| Glycine Plasma Membrane Transport Proteins | 1 | 2012 | 1 | 0.090 |
Why?
|
| Lymphocyte Count | 2 | 2013 | 73 | 0.090 |
Why?
|
| Homeostasis | 3 | 2020 | 368 | 0.090 |
Why?
|
| Forkhead Transcription Factors | 3 | 2020 | 128 | 0.090 |
Why?
|
| Mice, Inbred DBA | 3 | 2012 | 84 | 0.090 |
Why?
|
| Joints | 1 | 2012 | 33 | 0.090 |
Why?
|
| Retroelements | 1 | 2012 | 44 | 0.090 |
Why?
|
| Cell Communication | 1 | 2012 | 130 | 0.090 |
Why?
|
| Mutagenesis, Insertional | 1 | 2012 | 89 | 0.090 |
Why?
|
| Calcium, Dietary | 1 | 2011 | 29 | 0.090 |
Why?
|
| Neuromuscular Junction | 1 | 2012 | 77 | 0.090 |
Why?
|
| CD40 Ligand | 5 | 2016 | 158 | 0.090 |
Why?
|
| Plasma Cells | 1 | 2011 | 52 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 790 | 0.090 |
Why?
|
| Glutamate Decarboxylase | 3 | 2013 | 22 | 0.090 |
Why?
|
| Mice, 129 Strain | 1 | 2011 | 41 | 0.090 |
Why?
|
| Animals, Genetically Modified | 1 | 2012 | 290 | 0.090 |
Why?
|
| Genetic Linkage | 1 | 2011 | 96 | 0.090 |
Why?
|
| Coculture Techniques | 1 | 2011 | 96 | 0.090 |
Why?
|
| Asthma | 1 | 2015 | 459 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 130 | 0.090 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 136 | 0.090 |
Why?
|
| Genes, MHC Class I | 2 | 2018 | 27 | 0.080 |
Why?
|
| Immunoglobulins | 1 | 2010 | 77 | 0.080 |
Why?
|
| Peptide Library | 3 | 2008 | 37 | 0.080 |
Why?
|
| Vaccines, DNA | 1 | 2011 | 98 | 0.080 |
Why?
|
| Intermediate Filament Proteins | 1 | 2010 | 19 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 140 | 0.080 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2010 | 112 | 0.080 |
Why?
|
| Lysosomes | 1 | 2011 | 166 | 0.080 |
Why?
|
| Molecular Sequence Data | 3 | 2014 | 1991 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 454 | 0.080 |
Why?
|
| B7-1 Antigen | 1 | 2009 | 73 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2025 | 1469 | 0.080 |
Why?
|
| Graft Rejection | 3 | 2005 | 293 | 0.080 |
Why?
|
| Protein Engineering | 1 | 2009 | 82 | 0.080 |
Why?
|
| Salivary Glands | 2 | 2020 | 46 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2008 | 181 | 0.070 |
Why?
|
| Genotype | 1 | 2011 | 663 | 0.070 |
Why?
|
| Immunologic Techniques | 1 | 2008 | 11 | 0.070 |
Why?
|
| Muramidase | 2 | 2010 | 46 | 0.070 |
Why?
|
| Lymphopenia | 2 | 2004 | 34 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 325 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 424 | 0.070 |
Why?
|
| Chimera | 1 | 2007 | 42 | 0.070 |
Why?
|
| Molecular Mimicry | 2 | 2004 | 31 | 0.070 |
Why?
|
| Hemocyanins | 1 | 2006 | 23 | 0.070 |
Why?
|
| Neurons, Afferent | 1 | 2006 | 17 | 0.070 |
Why?
|
| TRPV Cation Channels | 1 | 2006 | 20 | 0.060 |
Why?
|
| Rats | 3 | 2010 | 1980 | 0.060 |
Why?
|
| Species Specificity | 1 | 2007 | 334 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 2 | 2006 | 139 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2007 | 167 | 0.060 |
Why?
|
| Transplantation Chimera | 2 | 2020 | 40 | 0.060 |
Why?
|
| Cricetinae | 1 | 2006 | 367 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2007 | 177 | 0.060 |
Why?
|
| Homozygote | 2 | 2003 | 124 | 0.060 |
Why?
|
| Models, Immunological | 1 | 2005 | 85 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 2 | 2010 | 676 | 0.060 |
Why?
|
| Point Mutation | 1 | 2006 | 166 | 0.060 |
Why?
|
| Cell Aggregation | 1 | 2005 | 21 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2005 | 203 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2020 | 1513 | 0.060 |
Why?
|
| Cell Survival | 1 | 2006 | 575 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 4 | 2016 | 864 | 0.060 |
Why?
|
| Immunoconjugates | 1 | 2004 | 90 | 0.050 |
Why?
|
| Genetic Carrier Screening | 1 | 2004 | 15 | 0.050 |
Why?
|
| Paleontology | 1 | 2004 | 2 | 0.050 |
Why?
|
| RNA Editing | 1 | 2004 | 23 | 0.050 |
Why?
|
| Fossils | 1 | 2004 | 7 | 0.050 |
Why?
|
| Incidence | 2 | 2005 | 1377 | 0.050 |
Why?
|
| Hominidae | 1 | 2004 | 7 | 0.050 |
Why?
|
| Histocompatibility Testing | 1 | 2004 | 32 | 0.050 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2023 | 7 | 0.050 |
Why?
|
| Brain | 1 | 2012 | 1552 | 0.050 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 2003 | 13 | 0.050 |
Why?
|
| Molecular Weight | 1 | 2003 | 187 | 0.050 |
Why?
|
| Eye | 1 | 2003 | 54 | 0.050 |
Why?
|
| Glutens | 1 | 2023 | 15 | 0.050 |
Why?
|
| Biological Evolution | 1 | 2004 | 122 | 0.050 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2003 | 47 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2004 | 319 | 0.050 |
Why?
|
| Apoptosis | 2 | 2006 | 1079 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2004 | 298 | 0.050 |
Why?
|
| Chickens | 1 | 2002 | 95 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 284 | 0.050 |
Why?
|
| Cell Line | 1 | 2006 | 2040 | 0.050 |
Why?
|
| Heterozygote | 1 | 2002 | 170 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2025 | 276 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2004 | 496 | 0.050 |
Why?
|
| Time Factors | 4 | 2017 | 3768 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2021 | 22 | 0.050 |
Why?
|
| Proteolysis | 1 | 2023 | 145 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2014 | 612 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2006 | 540 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2003 | 263 | 0.040 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2021 | 2 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 2013 | 35 | 0.040 |
Why?
|
| Kinetics | 1 | 2003 | 763 | 0.040 |
Why?
|
| Lymphocytes | 2 | 2016 | 201 | 0.040 |
Why?
|
| Sex | 1 | 2020 | 5 | 0.040 |
Why?
|
| Janus Kinases | 1 | 2021 | 16 | 0.040 |
Why?
|
| Peripheral Tolerance | 1 | 2020 | 3 | 0.040 |
Why?
|
| Mouth Mucosa | 1 | 2021 | 24 | 0.040 |
Why?
|
| Immunologic Surveillance | 1 | 2021 | 22 | 0.040 |
Why?
|
| CD5 Antigens | 1 | 2020 | 18 | 0.040 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2020 | 25 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2020 | 30 | 0.040 |
Why?
|
| Acinar Cells | 1 | 2020 | 8 | 0.040 |
Why?
|
| Immunodominant Epitopes | 1 | 2020 | 57 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 615 | 0.040 |
Why?
|
| Genes, Immunoglobulin | 1 | 2019 | 34 | 0.040 |
Why?
|
| Lymphopoiesis | 1 | 2019 | 27 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2003 | 1149 | 0.040 |
Why?
|
| Animals, Congenic | 1 | 2019 | 4 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2019 | 196 | 0.040 |
Why?
|
| Diet | 1 | 2023 | 527 | 0.040 |
Why?
|
| Self Tolerance | 2 | 2010 | 20 | 0.040 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2020 | 99 | 0.040 |
Why?
|
| Deoxyribonucleases | 1 | 2019 | 32 | 0.040 |
Why?
|
| Interferon Type I | 1 | 2020 | 187 | 0.040 |
Why?
|
| Phenotype | 2 | 2017 | 1207 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 152 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 288 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2004 | 895 | 0.040 |
Why?
|
| Animal Husbandry | 1 | 2017 | 10 | 0.030 |
Why?
|
| Decontamination | 1 | 2017 | 12 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2017 | 61 | 0.030 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2016 | 8 | 0.030 |
Why?
|
| Feces | 1 | 2017 | 112 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2016 | 63 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2017 | 147 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2008 | 245 | 0.030 |
Why?
|
| Mice, Inbred C3H | 2 | 2008 | 176 | 0.030 |
Why?
|
| Aging | 2 | 2016 | 745 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 770 | 0.030 |
Why?
|
| Ligands | 1 | 2016 | 416 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2015 | 19 | 0.030 |
Why?
|
| Blindness | 1 | 2015 | 41 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2017 | 262 | 0.030 |
Why?
|
| Histocompatibility Antigen H-2D | 2 | 2004 | 6 | 0.030 |
Why?
|
| Exome | 1 | 2015 | 77 | 0.030 |
Why?
|
| Epitopes | 2 | 2008 | 290 | 0.030 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2014 | 18 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2014 | 50 | 0.030 |
Why?
|
| Peritoneum | 1 | 2014 | 30 | 0.030 |
Why?
|
| Transfection | 2 | 2008 | 694 | 0.030 |
Why?
|
| Dogs | 1 | 2015 | 325 | 0.030 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2013 | 13 | 0.030 |
Why?
|
| Cholera Vaccines | 1 | 2013 | 3 | 0.030 |
Why?
|
| Phylogeny | 1 | 2015 | 376 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2014 | 197 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 313 | 0.020 |
Why?
|
| Disease Resistance | 1 | 2012 | 24 | 0.020 |
Why?
|
| Genome | 1 | 2015 | 276 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 401 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 491 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 369 | 0.020 |
Why?
|
| Grooming | 1 | 2012 | 4 | 0.020 |
Why?
|
| Maze Learning | 1 | 2012 | 55 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 2012 | 29 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 120 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2011 | 50 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2011 | 78 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2012 | 204 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4694 | 0.020 |
Why?
|
| Insulinoma | 1 | 2010 | 5 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 39 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2010 | 68 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 84 | 0.020 |
Why?
|
| Adolescent | 1 | 2021 | 6245 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2010 | 52 | 0.020 |
Why?
|
| Camelids, New World | 1 | 2009 | 7 | 0.020 |
Why?
|
| Sharks | 1 | 2009 | 7 | 0.020 |
Why?
|
| Rabbits | 1 | 2010 | 333 | 0.020 |
Why?
|
| Adult | 2 | 2021 | 16823 | 0.020 |
Why?
|
| Complementarity Determining Regions | 1 | 2009 | 38 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2009 | 133 | 0.020 |
Why?
|
| Motor Activity | 1 | 2012 | 346 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2009 | 299 | 0.020 |
Why?
|
| Anxiety | 1 | 2012 | 425 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 702 | 0.020 |
Why?
|
| Substance P | 1 | 2006 | 38 | 0.020 |
Why?
|
| Capsaicin | 1 | 2006 | 18 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 182 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 268 | 0.020 |
Why?
|
| Receptors, Leptin | 1 | 2006 | 13 | 0.020 |
Why?
|
| Concanavalin A | 1 | 2006 | 40 | 0.020 |
Why?
|
| Corticosterone | 1 | 2006 | 23 | 0.020 |
Why?
|
| Epistasis, Genetic | 1 | 2006 | 42 | 0.020 |
Why?
|
| NAD | 1 | 2006 | 53 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2005 | 37 | 0.010 |
Why?
|
| Microspheres | 1 | 2005 | 56 | 0.010 |
Why?
|
| Eosinophils | 1 | 2005 | 48 | 0.010 |
Why?
|
| Myotonin-Protein Kinase | 1 | 2004 | 3 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2005 | 277 | 0.010 |
Why?
|
| Metalloporphyrins | 1 | 2004 | 3 | 0.010 |
Why?
|
| Peroxynitrous Acid | 1 | 2004 | 5 | 0.010 |
Why?
|
| Chromones | 1 | 2004 | 19 | 0.010 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2004 | 9 | 0.010 |
Why?
|
| Aged | 1 | 2021 | 14449 | 0.010 |
Why?
|
| Abatacept | 1 | 2004 | 65 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2004 | 59 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2005 | 201 | 0.010 |
Why?
|
| Morpholines | 1 | 2004 | 89 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2004 | 84 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2004 | 171 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 2003 | 16 | 0.010 |
Why?
|
| B7-2 Antigen | 1 | 2003 | 32 | 0.010 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2003 | 9 | 0.010 |
Why?
|
| Genes, T-Cell Receptor alpha | 1 | 2003 | 5 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 2003 | 37 | 0.010 |
Why?
|
| Middle Aged | 1 | 2021 | 17615 | 0.010 |
Why?
|
| Retinal Pigments | 1 | 2003 | 5 | 0.010 |
Why?
|
| Iris | 1 | 2003 | 3 | 0.010 |
Why?
|
| Aqueous Humor | 1 | 2003 | 4 | 0.010 |
Why?
|
| Anterior Chamber | 1 | 2003 | 4 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2004 | 198 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2006 | 412 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 2003 | 48 | 0.010 |
Why?
|
| Mutation | 1 | 2012 | 2612 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 156 | 0.010 |
Why?
|
| Cell Count | 1 | 2003 | 132 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2006 | 484 | 0.010 |
Why?
|
| COS Cells | 1 | 2003 | 175 | 0.010 |
Why?
|
| fas Receptor | 1 | 2003 | 57 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2003 | 209 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 102 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 99 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 878 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2004 | 311 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2003 | 224 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 936 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2003 | 162 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 641 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 1603 | 0.010 |
Why?
|
| Biomarkers | 1 | 2005 | 1408 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 5680 | 0.010 |
Why?
|